CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Conditions: Acute Leukemia of Ambiguous Lineage; Recurrent Acute Myeloid Leukemia; Recurrent Acute Undifferentiated Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Mixed Phenotype Acute Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myelo id Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Mixed Phenotype Acute Leukemia; Refractory Myelodysplastic Syndrome Interventions: Drug: Cladribine; Drug: Cyclophosphamide; Drug: Cyclosporine; Drug: Cytarabine; Biological: Filgrastim; Procedure: Hematopoietic Cell Transplantation; Drug: Mitoxantrone; Drug: Mycophenolate Mofetil; Drug: Mycophenolate Sodium; Radiation: Total-Body Irra diation Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Chronic Leukemia | Filgrastim | Leukemia | Myelodysplastic Syndrome | Neulasta | Neupogen | Research | Restasis | Sodium | Stem Cell Therapy | Stem Cells | Transplants